Duchenne Muscular Dystrophy clinical trials

Explore recruiting duchenne muscular dystrophy clinical trials.

Recruiting duchenne muscular dystrophy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Duchenne Muscular Dystrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Belgium, Italy, Netherlands, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44)

Spain, Belgium, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45)

Netherlands, Italy, Spain, Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An open-label study to collect safety and effectiveness information on long-term treatment with vamorolone in boys with Duchenne Muscular Dystrophy who have completed prior studies with vamorolone (The GUARDIAN Study)

Czechia, Spain, Belgium, Greece, Ireland, Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy

Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A PHASE 1/2, OPEN-LABEL, EXPLORATORY CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DT-DEC01 THERAPY IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY

Poland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Duchenne Muscular Dystrophy trials by city

Duchenne Muscular Dystrophy in Toronto Duchenne Muscular Dystrophy in Vancouver Duchenne Muscular Dystrophy in Montreal Duchenne Muscular Dystrophy in Calgary Duchenne Muscular Dystrophy in Edmonton Duchenne Muscular Dystrophy in Ottawa Duchenne Muscular Dystrophy in Winnipeg Duchenne Muscular Dystrophy in Quebec City Duchenne Muscular Dystrophy in Hamilton Duchenne Muscular Dystrophy in Kitchener Duchenne Muscular Dystrophy in London Duchenne Muscular Dystrophy in Halifax Duchenne Muscular Dystrophy in New York Duchenne Muscular Dystrophy in Los Angeles Duchenne Muscular Dystrophy in Chicago Duchenne Muscular Dystrophy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease